RxDoctor Payments Data

Daniel Daroszewski, MD

Ophthalmology · Baltimore, MDNPI 1073049987

Payments from drug & device makers

$4,214in general payments, 2019–2025

Across 101 payments — averaging $41.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Harrow Eye, LLC$356
  • Amgen$271
  • Sight Sciences, Inc.$258
  • Oyster Point Pharma, Inc.$233
  • Rxsight Inc$223
  • plus $1K from 13 others

What the payments were for

  • Speaking & faculty fees$180%
  • Food & beverage$4,05796%
  • Education$180%
  • Gifts$1213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,214 in reported general payments places this provider in the 70th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$192,277
Medicare patients
352
Services billed
927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate407$17,359
RestasisCyclosporine11$16,526
LumiganBimatoprost18$11,570
RhopressaNetarsudil Mesylate20$10,372
MieboPerfluorohexyloctane/Pf12$8,822
MoxifloxacinMoxifloxacin Hcl273$7,819
CombiganBrimonidine Tartrate/Timolol19$6,784
SimbrinzaBrinzolamide/Brimonidine Tart13$3,305
Bimatoprost13$2,378
Brimonidine Tartrate23$1,666
ValacyclovirValacyclovir Hcl34$1,653
Diclofenac Sodium136$1,503
Latanoprost64$1,024
Doxycycline Hyclate31$917
ErythromycinErythromycin Base69$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$164$34,88048 claims
Bausch & Lomb Americas Inc.Miebo$95$8,82212 claims
AlconSimbrinza$1,482$3,30513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →